Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine
Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine
Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine

Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine

Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine
Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine
Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine

Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine

In 2013, it was approved by NMPA, China.

The first combination vaccine in China. Included in the Chinese pharmacopoeia (2020 version).

No antibiotics were added during the production process. The standard of aluminium adjuvant was higher than that of 
European pharmacopoeia, and the adverse events were lower.

 

【Active constituent】

Effective components of Bordetella pertussis, Diphtheria toxoid, Tetanus toxoid, and Capsular polysaccharide of Haemophilus influenzae type b (Hib capsular polysaccharide).

【Strengths]

DTaP combined vaccine: 0.5ml per vial. 0.5 ml per single human dose; Hib conjugate vaccine: 0.5ml per prefiled syring. 0.5 ml per single human dose.

【Eligibles】

People over 3 months old.

【Shelf Life】

24 months